Cullinan Therapeutics, Inc. (CGEM): Cash & Equivalents
$88.33M
As of 2025-12-31
$78.64M
As of 2026-06-30
-17.3%
3-year compound annual growth
-12.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $88.33M | +6.4% | 2026-03-10, Balance as of period end |
| 2024-12-31 | $83.00M | -15.7% | 2026-03-10, Balance as of period end |
| 2023-12-31 | $98.43M | -37.0% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $156.15M | +161.2% | 2024-03-14, Balance as of period end |
| 2021-12-31 | $59.77M | -64.5% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $168.20M | n/a | 2022-03-17, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | 2025-12-31 | $88.33M | +6.4% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $129.88M | -42.1% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $34.47M | -40.1% |
| Vor Biopharma Inc. (VOR) | 2025-12-31 | $396.49M | +383.8% |
| Sana Biotechnology, Inc. (SANA) | 2025-12-31 | $71.87M | -43.7% |
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $51.69M | -31.3% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Scholar Rock Holding Corp (SRRK) | 2025-12-31 | $323.53M | +81.9% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $88.33M | -38.4% |
Compare CGEM, GLUE, RGNX, VOR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗